Helix BioMedix Inc. announced the promotion of Robin L. Carmichael to the position of Chief Executive Officer in addition to her current role as president. She will continue as a member of the company's board of directors. Ms. Carmichael will be responsible for all aspects of management of Helix BioMedix including P&L, operations, sales, marketing, business development, pharmaceutical and consumer product programs, and research and development.

She will report directly to the board of directors. R. Stephen Beatty, outgoing Chief Executive Officer, will continue to serve as the company's Chief Investor Officer and has been appointed as Executive Chairman of the board of directors. Mr. Beatty will be responsible for shareholder relations.

Ms. Carmichael joined the company in 2007 as Vice President of Marketing and Business Development. She was promoted to Chief Operating Officer in 2011, and later to President and Chief Operating Officer in 2015. A veteran of the industry, Ms. Carmichael has over 25 years of experience in the life sciences with a successful background in the dermatology, cosmeceutical and aesthetic markets.

Prior to joining Helix BioMedix, Ms. Carmichael was Chief Operating Officer of DERMAdoctor Inc. She also served as Vice President of Marketing at ProCyte Corporation, and later at Photomedex Inc. following its acquisition of ProCyte.